Literature DB >> 7511176

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

K Javaherian1, A J Langlois, D C Montefiori, K A Kent, K A Ryan, P D Wyman, J Stott, D P Bolognesi, M Murphey-Corb, G J Larosa.   

Abstract

It has been shown previously that the major neutralizing epitopes in simian immunodeficiency virus (SIV) are discontinuous and conformation dependent and that the V3 loop, in contrast to that of human immunodeficiency virus (HIV) type 1, does not by itself elicit neutralizing antibodies (K. Javaherian et al., Proc. Natl. Acad. Sci. USA 89:1418-1422, 1992). We now present data showing that on the basis of fractionation of infected macaque sera, protease digestion of the envelope, and binding properties of two neutralizing monoclonal antibodies to SIV and SIV-HIV chimeric envelope proteins, changes in V3 can disrupt the conformation-dependent neutralization region. The chimeric protein did not produce significant neutralizing antibodies against either SIV or HIV. We also report that neutralizing antibodies elicited by recombinant SIV envelope proteins of mac251 and B670 isolates cross-neutralize. Finally, we show that deglycosylation of the SIV envelope results in a molecule which binds neither soluble CD4 nor the neutralizing monoclonal antibodies being investigated here and does not elicit sera with a significant neutralizing titer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511176      PMCID: PMC236740     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2.

Authors:  Y Morikawa; J P Moore; A J Wilkinson; I M Jones
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

4.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160.

Authors:  H Takahashi; S Merli; S D Putney; R Houghten; B Moss; R N Germain; J A Berzofsky
Journal:  Science       Date:  1989-10-06       Impact factor: 47.728

5.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

6.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

7.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Authors:  M Girard; M P Kieny; A Pinter; F Barre-Sinoussi; P Nara; H Kolbe; K Kusumi; A Chaput; T Reinhart; E Muchmore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

8.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.

Authors:  E O Freed; D J Myers; R Risser
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

10.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

View more
  14 in total

1.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.

Authors:  Seth A Faith; Yingyun Wu; David Kuhrt; Jonathan D Steckbeck; Jodi K Craigo; Janice E Clements; Kelly Stefano Cole
Journal:  Virology       Date:  2010-02-11       Impact factor: 3.616

5.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.

Authors:  Welkin E Johnson; Hannah Sanford; Linda Schwall; Dennis R Burton; Paul W H I Parren; James E Robinson; Ronald C Desrosiers
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Authors:  Brian J Rybarczyk; David Montefiori; Philip R Johnson; Ande West; Robert E Johnston; Ronald Swanstrom
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Regions required for CD4 binding in the external glycoprotein gp120 of simian immunodeficiency virus.

Authors:  C B Doyle; U Bhattacharyya; K A Kent; J E Stott; I M Jones
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 9.  Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.

Authors:  Charles J Russell; Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2015-12-09       Impact factor: 5.217

10.  Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.

Authors:  S Matsushita; S Matsumi; K Yoshimura; T Morikita; T Murakami; K Takatsuki
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.